X0306 4 2019-04-02 0 0001437786 IMMUNE DESIGN CORP. IMDZ 0001238325 RINGO WILLIAM R C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE WA 98102 1 0 0 0 Stock Option (Rt to Buy) 5.60 2019-04-02 4 D 0 10000 D Common Stock 10000 0 D Stock Option (Rt to Buy) 4.05 2019-04-02 4 D 0 12500 D Common Stock 12500 0 D Stock Option (Rt to Buy) 1.31 2019-04-02 4 D 0 12500 D Common Stock 12500 0 D Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. Not Applicable. /s/ Stephen R. Brady, Attorney-In-Fact 2019-04-04